#TLSI

StockTitan

@stocktitan.net

1 week ago

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance The $46 million in growth capital raised through our recent public offering, will substantially broaden and accelerate these strategic initiatives and drive support broader adoption of the PEDD platform. Based on our performance and positive outlook for 2026, we are reaffirming our revenue guidance of $60 million to $62 million. Generated $13.2 million...

#TLSI TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

3 months ago

#TLSI TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

7 months ago

TriSalus Revenue Soars 52% as New Cancer Device Enhances Treatment Access, Path to Profitability Clear TriSalus delivers $11.2M Q2 revenue, launches TriNav FLX for improved tumor treatment access. Company projects 50% annual growth and positive EBITDA by 2026. See earnings details.

#TLSI TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

7 months ago

Breakthrough Thyroid Procedure Achieves 73% Size Reduction: New Clinical Data Reveals Game-Changing Results New pressure-enabled thyroid treatment demonstrates 100% clinical success rate and 73% volume reduction in 22-patient study. See complete efficacy data and safety profile.

#TLSI TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

7 months ago

TriSalus Preferred Stock Exchange Succeeds: 98% Holders Accept 3.3-to-1 Conversion Deal Nearly all preferred stockholders accepted 3.3:1 common stock exchange offer. Remaining shares face mandatory conversion at lower rate. See final terms.

#TLSI TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

www.stocktitan.net/news/TLSI/tri-salus-life...

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks in new downtrend in Average Directional Index, Wed Jun 25th - #TLSI #ACTU #WEST #TCPC #SANW #HITI #FPAY #XPOF #SEMR #AVD - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

8 months ago

TriSalus Preferred Stock Exchange Offer: 11.8M Common Shares Up for Grabs as 55% Holders Back Deal Major capital restructuring sees TriSalus offering 11.8M common shares for preferred stock conversion. 55% of holders already committed. See full exchange terms before July deadline.

#TLSI TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

9 months ago

TriSalus Unveils Next-Gen Cancer Treatment Device: New TriNav FLX Shows 28% Better Navigation New TriNav FLX offers 28% reduced force navigation and enhanced flexibility for complex vascular procedures. Now with dual reimbursement coverage. See full specs.

#TLSI TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

9 months ago

TriSalus Life Sciences Reports Massive 42% Revenue Growth, Expands Oncology Tech Platform with Fresh $22M Backing Q1 earnings reveal 84% gross margins and expanded TriNav applications. Company updates 2025 guidance amid strategic pivot and $22M capital raise. See full financial details.

#TLSI TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

10 months ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results TriSalus Life Sciences has secured a $22.0 million private placement and reported preliminary Q1 2025 revenue of $9.2 million, marking a 42% growth compared to Q1 2024. The revenue was driven entirely by the TriNav® Infusion System. The private placement, led by Nantahala Capital with participation from Broadfin Holdings and other healthcare-focused investors, will issue 5,500,000 shares at $4.00 per share. Canaccord Genuity serves as the sole placement agent, with closing expected around May 2, 2025. Additionally, TriSalus is simplifying its capital structure through a planned exchange offer for Series A Convertible Preferred Stock. The company has secured support from holders representing 55% of outstanding Preferred Stock. The exchange offer will allow conversion to common stock at $10.00 per Preferred Share plus accrued dividends, divided by $4.00 per share.

#TLSI TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

11 months ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update TriSalus Life Sciences (NASDAQ: TLSI) reported strong financial results for Q4 and full-year 2024, with revenues reaching $8.3 million in Q4 and $29.4 million for the full year, showing growth of 44% and 59% respectively versus prior year periods. The company maintained impressive gross margins of 85% in Q4 and 86% for 2024.Key developments include the launch of TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels, expanding their addressable market to $375 million. The company completed enrollment in the PERIO-03 Phase 1 trial for pancreatic cancer, with final data expected mid-2025.For 2025, TriSalus reaffirmed guidance projecting over 50% revenue growth, more than 20% reduction in operating expenses, positive EBITDA, and positive cash flow in H2 2025. The company ended 2024 with $8.5 million in cash and expects sufficient runway throughout 2025.

#TLSI TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

11 months ago

Medicare Approves $11K+ Reimbursement for TriNav Cancer Treatment System - Major Win for Hospitals New CMS code validates TriNav's innovative pressure-driven technology for cancer treatment mapping. $11,341 reimbursement covers hospital and surgical center procedures. Full analysis inside.

#TLSI TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

www.stocktitan.net/news/TLSI/tri-salus-life...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks with strong volume declines, Mon Mar 17th - #XWEL #USAR #TLSI #REVB #BAOS #CLPR #KUKE #RLX #AIFU #CISO #IKNA #INFN #PFC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Revenue Success: TriSalus Unlocks $10M Strategic Funding from Healthcare Giant OrbiMed TriSalus Life Sciences achieves key $30M revenue milestone, enabling $10M drawdown from OrbiMed credit facility. Company has now accessed $35M total from the agreement.

#TLSI TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

www.stocktitan.net/news/TLSI/tri-salus-life...

StockTitan

@stocktitan.net

1 year ago

#TLSI TriSalus Reports Q3 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/TLSI/tri-salus-repo...